RE:RE:RE:If you haven’t listened to Earnings call…Exactly this. And I hope now we can move away from the 52 strong and late stage clinical trial nonsense as they now have put a bullet square in the head of that.
That said, the transcript was very telling and provided some fairly positive feel, but as has come LABS standard, it was almost all sizzle and no real steak. Lots of the expected 'soon's and 'expected's etc etc but nothing solid even though they seemed to have a chance to substantiate some of their claims (like the 1.5m Drob shipments, if that's true, what's the full year guidance? and if STADA is so great and we're so impressed by the #2 oils position, why has their impact on LABS been damn near zero? I wasn't aware that the market size for oils in Germany was a bit more than damn near zero).
Also of note, management clearly had a strategy when speaking about the share price and how it is undervalued. Some people may naively take this as their greed kicking in with the recent lottery win of RSUs they gifted themselves, however I expect it has much more to do with the fact that they have already decided on a reverse split and they desperately want/need the SP to move materially higher before putting the knife into the backs of many a shareholder. Doing a RS at any level is bad, but doing it at all time lows, well the optics are just awful and I presume they even have their standards to maintain even if they don;t much care about the little guy.
Either way, the results and call were meh. Q1 hopefully will have more to tell.
"Thanks for posting the link. Interesting read. Definitely on solid footing but nothing that's going to trigger any kind of explosive growth in the share price, especially fromthe pharma side.
As Keith discussed previously, pharmaceutical revenue is a longer-term strategy and will take time to pay off as clinical trials progress and applications make their way through the long-term process of approvals.
Slow and steady climb probably starting next earnings. "